[Surgical treatment of thymoma--clinical evaluation].
Sixty-seven patients with thymoma were surgically treated during the past 19 years in our department. The 5-year, 10-year and 15-year survival rates of total cases with thymomas were 69.2%, 59.6% and 59.6%, respectively. Survival rates of thymoma with MG and without MG were not significantly different. According to clinical stages in Masaoka's classification, there were significant difference between Stage I and Stag III (p < 0.05), Stage I and Stage IV a (p < 0.01), and Stage I and Stage IV b (p < 0.01). We can conclude that complete resection of thymomas lead to better prognosis, and immunochemotherapy using cyclophosphamide, vincristine and OK-432 are effective.
Ietsugu
K
K
Department of Surgery, Kanazawa University School of Medicine, Japan.
Shimizu
J
J
Murakami
S
S
Oda
M
M
Hayashi
Y
Y
Tatsuzawa
Y
Y
Kobayashi
K
K
Sekido
N
N
Arano
Y
Y
Takahashi
A
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage; D011379:Prognosis; D015996:Survival Rate; D013945:Thymoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D013953:Thymus Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D014750:Vincristine / Q000008:administration & dosage
D010844:Picibanil; D014750:Vincristine; D003520:Cyclophosphamide